https://www.techdirt.com/2023/09/18/ftc-warns-pharma-companies-that-it-may-go-after-them-for-sham-patent-listings-designed-to-delay-generic-competitors/ [ ] Techdirt. [ ] * Sign In * Register * Preferences Techdirt [ ] * TechDirt * GreenHouse * Free Speech * Deals * Jobs * Support Techdirt [podcast-ti] Police Union VP Says Woman Killed By Cop Is Only Worth $11,000 Appeals Court Says Michigan County's Vehicle Forfeiture Program Is Unconstitutional FTC Warns Pharma Companies That It May Go After Them For Sham Patent Listings Designed To Delay Generic Competitors [patents] Patents from the abusing-the-orange-book,-green-with-greed dept Mon, Sep 18th 2023 01:30pm - Mike Masnick For many, many years we've detailed how big pharma companies, who only care about the monopoly rents they can receive on medicine while under patent, have concocted all sorts of scams and schemes to avoid having to compete with generic versions, even after their patents have expired (or been invalidated). But one of their older tricks is apparently popular yet again, though the FTC is now warning pharma that it might finally start cracking down. If it does, it will just be reinforcing the kinds of actions the FTC used to bring. Twenty years ago, the FTC went after Bristol Meyer Squibb for false listings in the Orange Book. The Orange Book, managed by the FDA, is where pharma companies list the FDA-approved drugs they have under patent, which alerts generic drug companies basically not to make generic versions of those drugs. But, of course, this creates a very tempting scenario: if pharma can get drugs not actually under patent into the Orange Book, they effectively save themselves from generic competition, and they get to profit massively (at the expense of the public and their need for affordable medicine). However, despite enforcement against such abuse years ago, it seems that the FTC and the FDA have kinda let these things slip over the past few years. And Big Pharma has really taken advantage of that. Thankfully, it looks like the FTC is finally interested in cracking down on this practice again. In a new policy statement, it warns pharma companies that it's looking into the abuse of the Orange Book and sham patent inclusions. Brand drug manufacturers are responsible for ensuring their patents are properly listed. Yet certain manufacturers have submitted patents for listing in the Orange Book that claim neither the reference listed drug nor a method of using it. When brand drug manufacturers abuse the regulatory processes set up by Congress to promote generic drug competition, the result may be to increase the cost of and reduce access to prescription drugs. The goal of this policy statement is to put market participants on notice that the FTC intends to scrutinize improper Orange Book listings to determine whether these constitute unfair methods of competition in violation of Section 5 of the Federal Trade Commission Act. Of course, this raises some questions, including why do we make the pharma companies themselves the party responsible for making sure their patents are "properly" listed. Why don't we have at least some process in place for these listings to be reviewed, whether when they're submitted to the Orange Book or even if another party (such as the generic drug manufacturers) contest an Orange Book listing. It seems the dumbest possible system is to assume that the Big Pharma companies will be honest in their Orange Book listings. And, even though the FTC is now putting these companies "on notice," the fact that the FTC has brought these cases in the past seems like it should be "notice" enough. Instead, it sounds like the FTC let enough pharma companies get away with this for long enough that the big pharma firms felt cleared to abuse the system this way and to delay competition in the marketplace. The one thing I find interesting in this statement, is that they note that improperly listing things in the Orange Book may "constitute illegal monopolization." The improper listing of patents in the Orange Book may also constitute illegal monopolization. Monopolization requires proof of "the willful acquisition or maintenance of [monopoly] power as distinguished from growth or development as a consequence of a superior product, business acumen, or historic accident." This requires proof that "the defendant has engaged in improper conduct that has or is likely to have the effect of controlling prices or excluding competition," and courts have recognized that improperly listing patents in the Orange Book may constitute an "improper means" of competition. Accordingly, improperly listing patents in the Orange Book may also be worthy of enforcement scrutiny from government and private enforcers under a monopolization theory. Additionally, the FTC may also scrutinize a firm's history of improperly listing patents during merger review This seems exactly correct, but notable in that very few people seem to recognize that (1) patents are government granted monopolies, and thus (2) an abuse of the patent system to get a patent or patent-like protections you don't deserve are therefore an illegal monopoly seems like an important point. I would hope that this could get expanded to other abuses of patent and copyright law as well. Still, given that we've been facing this and multiple other schemes from Big Pharma to delay generics for decades, I'm not sure anything is really going to change just yet, but at least the FTC is waking up (again?) to this issue. Now let's see if it actually starts bringing cases... Filed Under: competition, drug prices, ftc, generics, monopoly, orange book, patents, pharma 3 CommentsLeave a Comment If you liked this post, you may also be interested in... * A New Low: Just 46% Of U.S. Households Subscribe To Traditional Cable TV * Judge For FTC Rules Intuit Can't Continue Its 'Free To File' Advertising Bullshit * First Of Potentially Many Google Antitrust Claims Goes To Trial * DOJ To Court: Here Are The Many, Many Reasons Why The FTC Can & Should Be Investigating Elon Musk's Handling Of User Data * The EU Designates The Six Companies You Already Expected As 'Gatekeepers' Under The Digital Markets Act * * * Rate this comment as insightful Rate this comment as funny You have rated this comment as insightful You have rated this comment as funny Flag this comment as abusive/trolling/spam You have flagged this comment The first word has already been claimed The last word has already been claimed Lightbulb icon Laughing icon Flag icon Lightbulb icon Laughing icon Comments on "FTC Warns Pharma Companies That It May Go After Them For Sham Patent Listings Designed To Delay Generic Competitors" Subscribe: RSS Leave a comment * Filter comments in by Time * Filter comments as Threaded * Filter only comments rated Insightful * Filter only comments rated funny LOL * Filter only comments that are Unread 3 Comments [user-default]That One Guy (profile) says: September 18, 2023 at 1:38 pm 'How dare you, that was .000001% of our profit during that time!' Pharma companies aren't trying to stymie and keep generics off the market because they're bored and looking for something to do they're doing it because it's hugely profitable to do so so unless the FTC is willing to hand out some massive financial penalties in amounts that are at a minimum equal to how much the companies have been getting from squashing generics all they're really going to do here is turn 'getting caught keeping generics off the market for a few more years' into just another business expense. It's a good idea but only if they're willing to fully commit to it as far from a warning or penalty any token effort is likely to be treated as encouragement and confirmation that the behavior they are trying to stop is hugely profitable even when you get caught. Reply View in chronology Make this comment the first word Make this comment the last word [d02bae43cb]mick says: September 18, 2023 at 1:54 pm It really doesn't look like that Thankfully, it looks like the FTC is finally interested in cracking down on this practice again. In a new policy statement, it warns pharma companies that it's looking into the abuse of the Orange Book and sham patent inclusions. No, it doesn't look like they're interested in cracking down on anything. It looks like they've chosen a performative warning over taking action. You could argue that this is a good first step, but I'd argue that it's a joke. It will look like they're interested in cracking down when they start, you know, cracking down on someone for something. Until then, nothing at all has changed. Reply View in chronology Make this comment the first word Make this comment the last word [0acc3ca4c5]Anonymous Coward says: September 18, 2023 at 3:57 pm Why don't we have at least some process in place for these listings to be reviewed, whether when they're submitted to the Orange Book. ... because a half million a year (5 highly trained positions, or 2 highly trained and 6 google-monkeys) looks like a lot on a budget, and the pharma lobby knows how to press "skimp on budget" buttons. Reply View in chronology Make this comment the first word Make this comment the last word --------------------------------------------------------------------- says: Add Your Comment Cancel reply Your email address will not be published. Required fields are marked * Have a Techdirt Account? Sign in now. Want one? Register here Name [ ] Email [ ] [ ]Subscribe to the Techdirt Daily newsletter URL [ ] Subject [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] Comment * [ ] Comment Options: (*)Use markdown. ( )Use plain text. Make this the ( )First Word or ( )Last Word.(*)No thanks. (get credits or sign in to see balance) what's this? What's this? Techdirt community members with Techdirt Credits can spotlight a comment as either the "First Word" or "Last Word" on a particular comment thread. Credits can be purchased at the Techdirt Insider Shop >> [Post Comment][Preview] [ ] [ ] [ ] [ ] [ ] [ ] [ ] D[ ] Police Union VP Says Woman Killed By Cop Is Only Worth $11,000 Appeals Court Says Michigan County's Vehicle Forfeiture Program Is Unconstitutional Follow Techdirt Techdirt Daily Newsletter [ ] [Subscribe] Essential Reading The Techdirt Greenhouse Read the latest posts: * Winding Down Our Latest Greenhouse Panel: The Lessons Learned From SOPA/PIPA * From The Revolt Against SOPA To The EU's Upload Filters * Did We Miss Our Best Chance At Regulating The Internet? Read All >> --------------------------------------------------------------------- Trending Posts * The Batshit Crazy Story Of The Day Elon Musk Decided To Personally Rip Servers Out Of A Sacramento Data Center * Social Engineering Meets Hacking With Prompt Hacking * FTC Warns Pharma Companies That It May Go After Them For Sham Patent Listings Designed To Delay Generic Competitors Techdirt Deals Techdirt Insider Discord The latest chatter on the Techdirt Insider Discord channel... Loading... Become an Insider! Recent Stories Monday 13:30 FTC Warns Pharma Companies That It May Go After Them For Sham Patent Listings Designed To Delay Generic Competitors (3) 12:00 Police Union VP Says Woman Killed By Cop Is Only Worth $11,000 (16) 10:53 Bill Willingham Says Fables Is Released To The Public Domain, DC Comics Says It Most Certainly Is Not (18) 10:48 Daily Deal: Microsoft Windows 11 Pro (0) 09:24 Intelligence Community Feels It Might Be Time To Start Stuffing Surveillance Gear Into People's Pants (15) 05:27 A New Low: Just 46% Of U.S. Households Subscribe To Traditional Cable TV (7) Sunday 12:04 Funniest/Most Insightful Comments Of The Week At Techdirt (22) Saturday 13:00 This Week In Techdirt History: September 9th - 16th (1) Friday 19:39 Eighth Circuit Says Cops Can Come With Probable Cause For An Arrest AFTER They've Already Arrested Someone (23) 15:48 Internet Archive Kicks Off Its Appeal Over Publishers Attempt To Kill The Site (13) More arrow x Email This Story This feature is only available to registered users. You can register here or sign in to use it. Tools & Services * Twitter * Facebook * RSS * Podcast * Research & Reports Company * About Us * Advertising Policies * Privacy Contact * Help & Feedback * Media Kit * Sponsor / Advertise More * Copia Institute * Insider Shop * Support Techdirt Techdirt Brought to you by Floor64 Proudly powered by WordPress. Hosted by Pressable. [Got it] This site, like most other sites on the web, uses cookies. For more information, see our privacy policy